TOKYO (Reuters) – Chugai Pharmaceutical Co said on Tuesday it applied for regulatory approval in Japan of an antibody treatment for COVID-19.
The filing is for the antibody cocktail casirivimab and imdevimab and is based on results from a global phase III study and a phase I trial in Japan. Chugai in December in-licensed the drug from Roche, which has a controlling stake in the Japanese company.
(Reporting by Rocky Swift, editing by Louise Heavens)
